Wallenius Wilhelmsen invites investors, lenders, analysts, and media to Q1 2026 results presentation at Strandveien 20, 1366 Lysaker, Norway; Live webcast with Q&A

Wallenius Wilhelmsen invites investors, lenders, analysts, and media to Q1 2026 results presentation at Strandveien 20, 1366 Lysaker, Norway; Live webcast with Q&A Wallenius Wilhelmsen: Invitation to Q1 2026 results presentation Wallenius Wilhelmsen: Invitation to Q1 2026 results presentation Wallenius Wilhelmsen is pleased to invite investors, lenders, analysts, and media to the presentation of our first quarter 2026 results. Date: Wednesday, May 6, 2026 Time: 08:30 AM Presenters: Lasse Kristoffersen (President & CEO) and Bjørnar Bukholm (CFO) The presentation will be held at Wallenius Wilhelmsen’s head office, located at: Strandveien 20, 1366 Lysaker, Norway. The presentation will be streamed live as a video webcast on the following link: https: ...

April 27, 2026

AstraZeneca: FDA erteilt Zulassung für Saphnelo in den USA; US-Zulassung stärkt Umsatzpotenzial

AstraZeneca: FDA erteilt Zulassung für Saphnelo in den USA; US-Zulassung stärkt Umsatzpotenzial Update Aktien International Börsennews 27. April 2026 Aktien International – Update Täglicher Marktkommentar aus dem BEKB-Handelsraum Übersicht European Futures Euro Stoxx 50 5'880 0.8 % DAX 24'481 0.9 % CAC 40 8'131 0.7 % FTSE 100 10'418 0.2 % US-Futures Dow Jones Industrial 49'347 0.1 % Nasdaq 100 27'487 0.2 % S&P 500 7'197 0.0 % News Europa ...

April 27, 2026